Evoke Pharma, Inc. (EVOK)

Evoke Pharma, Inc. (EVOK) Healthcare & Pipeline Overview

Evoke Pharma, Inc. is a specialized pharmaceutical company dedicated to addressing digestive system illnesses, with its lead product, Gimoti, a metoclopramide nasal spray, targeting acute and recurrent diabetic gastroparesis in female patients. The company focuses on a unique delivery method for an established therapeutic agent within a niche market segment.

What Is the Investment Thesis for EVOK?

Evoke Pharma, Inc. presents an investment thesis centered on the commercialization potential of its lead product, Gimoti, a metoclopramide nasal spray for diabetic gastroparesis, particularly in female patients. With a market capitalization of $18.95M, the company operates with a high gross margin of 97.0%, indicating strong pricing power or efficient cost of goods sold for its product. The unique nasal spray delivery method for metoclopramide offers a differentiated value proposition in a market where oral administration can be problematic due to nausea and vomiting, common symptoms of gastroparesis. Key growth catalysts include increasing prescription trends for Gimoti, successful market penetration within the targeted healthcare professional segments, and securing favorable reimbursement policies from payers. However, as a single-product company, Evoke Pharma faces significant inherent risks tied directly to Gimoti's market acceptance and commercial success. The current negative profit margin of -36.2% underscores the critical need for robust sales growth and operational efficiency to achieve profitability. Investors should closely monitor the company's ability to expand its market share and manage its commercialization expenses effectively.

Based on FMP financials and quantitative analysis

EVOK Key Highlights

• Market Capitalization stands at $0.02 billion, reflecting its status as a small-cap pharmaceutical company.
• Achieved a high Gross Margin of 97.0%, indicating strong profitability on sales of its product.
• Reports a Profit Margin of -36.2%, signaling current unprofitability as it focuses on commercialization and operational expenses.
• Operates with a lean structure, employing 3 individuals, which can impact scalability and breadth of operations.
• Beta of -0.14 suggests a low correlation with the broader market, potentially indicating less volatility than the overall market or unique market drivers.

Who Are EVOK's Competitors?

EVOK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EVOK's Key Strengths?

• Unique nasal spray delivery method for metoclopramide (Gimoti) addressing patient compliance issues.
• High gross margin of 97.0% indicates strong product economics post-sales.
• Specialized focus on digestive system illnesses, particularly diabetic gastroparesis, allows for targeted market efforts.
• Gimoti has completed Phase 3 clinical trials, demonstrating regulatory progress.

What Are EVOK's Weaknesses?

• Operates as a single-product company, creating significant reliance on Gimoti's commercial success.
• Negative profit margin of -36.2% indicates current unprofitability and high operational costs relative to revenue.
• Small employee base of 3 people may limit scalability and breadth of commercialization efforts.
• Market acceptance and securing favorable reimbursement for Gimoti remain critical challenges.

What Could Drive EVOK Stock Higher?

• Increased prescription volumes and market adoption of Gimoti among digestive disease specialists and general practitioners, demonstrating successful commercialization efforts.
• Securing additional favorable reimbursement agreements with major payers, which would expand patient access and reduce out-of-pocket costs, thereby boosting sales.
• Public release of data indicating sustained growth in Gimoti's market share and revenue, signaling positive commercial trajectory.
• Potential announcement of new strategic partnerships aimed at expanding Gimoti's distribution or exploring new therapeutic applications.

What Are the Key Risks for EVOK?

• Financial-distress signal — its Altman Z-Score of -10.78 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $3.8M recently.
• **Single-Product Dependency:** Evoke Pharma's financial performance is almost entirely dependent on the commercial success of Gimoti. Any issues with market acceptance, competition, or reimbursement for Gimoti could severely impact the company's revenue and profitability.
• **Market Acceptance and Reimbursement Challenges:** Despite Gimoti's unique delivery, achieving widespread market acceptance and securing favorable reimbursement from a broad range of payers remains an ongoing challenge. Payer decisions significantly influence patient access and physician prescribing habits.
• **Intense Competition:** The pharmaceutical market for gastrointestinal disorders is competitive. Existing treatments and potential new entrants, including generic versions of metoclopramide or other prokinetics, could limit Gimoti's market share and pricing power.
• **Financial Performance and Profitability:** The company currently operates with a negative profit margin. Sustained unprofitability or insufficient cash flow to support commercialization and potential future development could pose a significant financial risk.

What Are the Growth Opportunities for EVOK?

• Growth opportunity 1: **Expanding Market Penetration for Gimoti in Diabetic Gastroparesis** Evoke Pharma's primary growth driver lies in deepening the market penetration of Gimoti for acute and recurrent diabetic gastroparesis, particularly among female patients. The market for gastroparesis treatments is significant, with diabetic gastroparesis affecting a substantial portion of the diabetic population. Gimoti's unique nasal spray delivery offers a distinct advantage over oral medications, especially for patients experiencing nausea and vomiting, potentially leading to increased adoption. Successful execution of marketing and sales strategies targeting digestive disease specialists, internists, and general practitioners will be crucial in capturing a larger share of this market, with ongoing efforts to educate healthcare providers on its benefits and appropriate patient selection.
• Growth opportunity 2: **Potential Label Expansion for Gimoti** While currently indicated for female patients, there is a potential long-term opportunity for Evoke Pharma to explore label expansion for Gimoti. This could include investigating its efficacy and safety in male patients with diabetic gastroparesis or exploring its utility in gastroparesis caused by other etiologies, such as idiopathic gastroparesis. Such expansions would significantly broaden the addressable patient population and market size for Gimoti. This would likely involve additional clinical trials and regulatory submissions, representing a future growth vector with a timeline dependent on clinical outcomes and regulatory approvals.
• Growth opportunity 3: **Development of New Therapeutic Agents for Digestive Illnesses** Evoke Pharma's stated focus on inventing and bringing to market therapeutic agents for various digestive system illnesses suggests a potential for pipeline diversification beyond Gimoti. Identifying and developing new drug candidates for other gastrointestinal disorders, either through internal research or in-licensing opportunities, could provide future revenue streams and reduce reliance on a single product. This strategy would require substantial R&D investment and a long development timeline, but it represents a significant opportunity to leverage the company's expertise in the gastrointestinal therapeutic area and expand its market presence.
• Growth opportunity 4: **Strategic Partnerships and Licensing Agreements** Given its small operational footprint and specialized product, Evoke Pharma could pursue strategic partnerships or licensing agreements to enhance Gimoti's commercial reach or accelerate the development of future pipeline candidates. Collaborations with larger pharmaceutical companies could provide access to broader sales forces, deeper market penetration, and additional resources for geographic expansion or new product development. Such partnerships could unlock significant value by leveraging external capabilities, particularly in areas like international distribution or specialized marketing, with potential timelines for such agreements varying based on market conditions and partner interest.
• Growth opportunity 5: **Geographic Expansion Beyond Current Distribution** While the current distribution focuses on healthcare professionals within the US, there is a potential long-term growth opportunity to explore international markets for Gimoti. Diabetic gastroparesis is a global health concern, and securing regulatory approvals and establishing distribution channels in key international markets could significantly expand Evoke Pharma's revenue base. This would involve navigating complex international regulatory landscapes, understanding diverse healthcare systems, and potentially forming partnerships with local pharmaceutical companies. The timeline for such expansion would be extensive, requiring careful strategic planning and significant capital investment.

What Opportunities Does EVOK Have?

• Expanding market penetration for Gimoti within the targeted diabetic gastroparesis patient population.
• Potential for label expansion of Gimoti to broader patient demographics or other gastroparesis etiologies.
• Strategic partnerships or licensing agreements to enhance commercial reach and accelerate development.
• Development of new therapeutic agents for other unmet needs in digestive system illnesses.

What Threats Does EVOK Face?

• Intense competition from existing and emerging treatments for gastroparesis.
• Challenges in securing favorable reimbursement policies from payers, impacting patient access and sales volume.
• Risk of market acceptance not meeting expectations, leading to slower-than-anticipated sales growth.
• Regulatory hurdles and potential for new competitive products to enter the market.

What Are EVOK's Competitive Advantages?

• **Unique Delivery Method:** Gimoti's nasal spray formulation offers a differentiated administration route for metoclopramide, potentially improving patient compliance and efficacy, especially for those with nausea and vomiting.
• **Targeted Indication:** Focus on acute and recurrent diabetic gastroparesis in female patients addresses a specific, often underserved, patient population with distinct needs.
• **Regulatory Approval:** Having completed Phase 3 clinical trials and secured regulatory approval for Gimoti provides a significant barrier to entry for competitors attempting to introduce similar products.
• **Specialized Expertise:** The company's exclusive focus on digestive system illnesses allows for deep specialization and understanding of the market and patient needs within this therapeutic area.

What Does EVOK Do?

Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. Established in 2007, the company's corporate offices are situated in Solana Beach, California, reflecting its origins and continued base in a hub for biotechnology innovation. Evoke Pharma distinguishes itself by concentrating on specific, unmet medical needs within gastrointestinal disorders. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has successfully progressed through and completed its Phase 3 clinical trials. This medicine is specifically being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, with a particular focus on female patients who often experience more severe or distinct symptoms. Gimoti represents a novel delivery method for metoclopramide, a known prokinetic agent, offering an alternative for patients who may have difficulty with oral medications or require a different pharmacokinetic profile. Evoke Pharma's distribution strategy targets a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers, ensuring a wide reach for its specialized therapeutic offerings. The company's operational model emphasizes focused development and commercialization within its niche, aiming to provide innovative solutions for patients suffering from challenging gastrointestinal conditions.

What Products and Services Does EVOK Offer?

• Develop and commercialize therapeutic agents specifically for digestive system illnesses.
• Their primary product is Gimoti, a metoclopramide nasal spray.
• Gimoti is designed to relieve symptoms of acute and recurrent diabetic gastroparesis.
• The target patient population for Gimoti is primarily female adults with diabetic gastroparesis.
• Distribute their product to a wide range of healthcare professionals, including digestive disease specialists, internists, and general practitioners.
• Focus on providing a unique delivery method (nasal spray) for an established medication.
• Operate as a specialized pharmaceutical entity from Solana Beach, California.

How Does EVOK Make Money?

• Generate revenue through the sale of their proprietary pharmaceutical product, Gimoti, to healthcare providers.
• Focus on commercializing Gimoti by targeting specific medical specialists and general practitioners.
• Potentially explore licensing agreements or partnerships for broader market access or future product development.
• Invest in research and development for new therapeutic agents, although Gimoti is currently their lead and sole commercial product.

What Industry Does EVOK Operate In?

Evoke Pharma, Inc. operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, specifically targeting gastrointestinal disorders. This sector is characterized by a constant demand for innovative therapeutic solutions, particularly for chronic conditions like diabetic gastroparesis where existing treatments may have limitations or side effects. Evoke Pharma's focus on a novel delivery method—a nasal spray—for an established drug like metoclopramide positions it within a segment seeking improved patient compliance and efficacy. The broader pharmaceutical market for gastrointestinal drugs is substantial, driven by increasing prevalence of digestive diseases and an aging population. However, the specialty and generic drug landscape is also marked by intense competition, regulatory hurdles, and the need for significant investment in clinical development and commercialization. Evoke Pharma's niche approach targets a specific patient population, aiming to carve out market share by addressing an unmet need for a more tolerable and effective administration route.

Who Are EVOK's Key Customers?

• Digestive disease specialists who treat patients with gastrointestinal disorders.
• Internists and general practitioners who manage diabetic patients and related complications.
• Other medical providers involved in the care of patients suffering from gastroparesis.
• Ultimately, patients suffering from acute and recurrent diabetic gastroparesis, particularly female patients.

How Evoke Pharma, Inc. Is Valued

Evoke Pharma, Inc. carries a market capitalization of $18.95M, placing it in the micro-cap category. Relative to its peer group, EVOK's quantitative score of 56/100 is below the peer average of 66/100.

Company Profile

Evoke Pharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Solana Beach, US. The company is led by CEO Mark A. Kowieski. EVOK has traded publicly since 2013.

Key Financial Metrics

Return on assets is -33.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Evoke Pharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.78 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Evoke Pharma, Inc. revenue of about $25.2M for fiscal 2026, with EPS near $0.68.

Net sellingInsider Activity

The most recent 12 insider filings for Evoke Pharma, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.3M shares disposed (about $3.8M), a signal worth weighing alongside the fundamentals.

EVOK Financials

EVOK Latest News

No recent news available for EVOK.

EVOK Analyst Consensus

EVOK MoonshotScore

Evoke Pharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources